Epidiolex, the first naturally-derived medical cannabis product produced by Big Pharma, is coming to America by early 2016 – and there’s no stopping it.
Manufactured by British company GW Pharmaceuticals, Epidiolex is a liquid formulation of pure, plant-derived cannabidiol (CBD) that has just entered the final Phase 3 study for the treatment of pediatric epilepsy disorders. Results are due for the first quarter of 2016.
There are indications that the government is speeding up the approval of this drug to the American market. For one, it is now placed on FDA Fast Track. Another sign was when Senators Charles Grassley of Iowa and Dianne Feinstein of California, both unlikely proponents of cannabis, supported “expanding compassionate access programs where possible, to benefit as many children as possible,” during a hearing about medical cannabis.
It is not the first time that a cannabis-based medication has sought approval from the FDA. Another product from GW Pharmaceuticals called Sativex is also waiting for approval from the FDA because of its CBD and THC content. It has already been approved for the treatment of muscle spasms in 27 countries.
GW Pharmaceuticals is further exploring the potential of marijuana in the treatment of other diseases, such as ulcerative colitis, diabetes, schizophrenia, epilepsy, cancer, and neurodegenerative diseases.
FDA’s impending approval of Epidiolex and Sativex can change the landscape of medicinal marijuana use. This could lend weight to the argument that cannabinoids have recognized medical use and should hence be reclassified as a legitimate drug.
How can the accessibility of cannabis-based drugs impact the public? Voice your opinions in the comments section below – your opinion matters to the nation.